Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G (1994) Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 54: 4744-4749.

CAS  PubMed  Google Scholar 

Trueba SS, Auge J, Mattei G, Etchevers H, Martinovic J, Czernichow P, Vekemans M, Polak M, Attie-Bitach T (2005) PAX8, TITF1, and FOXE1 gene expression patterns during human development: new insights into human thyroid development and thyroid dysgenesis-associated malformations. J Clin Endocrinol Metab 90: 455–462. jc.2004–1358. https://doi.org/10.1210/jc.2004-1358.

Tanda ML, Ippolito S (2022) Thyroid Hormones. In: La Rosa S., Uccella S, editors. Endocrine Pathology. Springer. pp. https://doi.org/10.1007/978-3-030-62345-6_5292.

Asa SL, Mete O (2021) Oncocytic change in thyroid pathology. Front Endocrinol (Lausanne) 12: 678119. https://doi.org/10.3389/fendo.2021.678119.

Baloch Z, Mete O, Asa SL (2018) Immunohistochemical biomarkers in thyroid pathology. Endocr Pathol 29: 91-112. https://doi.org/10.1007/s12022-018-9532-9.

Article  CAS  PubMed  Google Scholar 

Zhang X, Howell JM, Huang Y (2018) Cervical lymph node fine-needle aspiration and needle-wash thyroglobulin reflex test for papillary thyroid carcinoma. Endocr Pathol 29: 346-350. https://doi.org/10.1007/s12022-018-9547-2.

Article  CAS  PubMed  Google Scholar 

Kim H, Kim YN, Kim HI, Park SY, Choe JH, Kim JH, Kim JS, Chung JH, Kim TH, Kim SW (2017) Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer. Sci Rep 7: 16955. https://doi.org/10.1038/s41598-017-17176-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pacini F, Fuhrer D, Elisei R, Handkiewicz-Junak D, Leboulleux S, Luster M, Schlumberger M, Smit JW (2022) 2022 ETA Consensus Statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J 11. e210046. https://doi.org/10.1530/ETJ-21-0046.

Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simoes M, Tallini G, Mete O (2022) Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 33: 27-63. https://doi.org/10.1007/s12022-022-09707-3.

Article  PubMed  Google Scholar 

Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman E, Gill AJ, Ghossein R (2020) Dissecting Anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid 30: 1505-1517. https://doi.org/10.1089/thy.2020.0086.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306.

Article  CAS  PubMed  Google Scholar 

DeLellis, R. A., Lloyd, R. V., Heitz, P. U, and Eng, C. (2004) Pathology and genetics of tumours of endocrine organs. Lyons, France: IARC Press.

Google Scholar 

Lloyd, R. V., Osamura, R. Y., Kloppel, G., and Rosai, J. (2017) WHO Classification of Tumours of Endocrine Organs (4th edition), IARC: Lyon, 2017. Lyon: IARC.

Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, Rosai J (2007) Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31: 1256-1264.

Article  PubMed  Google Scholar 

Rindi G, Mete O, Uccella S, Basturk O, La RS, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33: 115-154. https://doi.org/10.1007/s12022-022-09708-2.

Article  CAS  PubMed  Google Scholar 

Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Kloppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31: 1770-1786. https://doi.org/10.1038/s41379-018-0110-y.

Article  PubMed  PubMed Central  Google Scholar 

Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, Shah JP, Singh B, Ghossein RA (2006) Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106: 1286-1295.

Article  PubMed  Google Scholar 

Xu B, David J, Dogan S, Landa I, Katabi N, Saliba M, Khimraj A, Sherman EJ, Tuttle RM, Tallini G, Ganly I, Fagin JA, Ghossein RA (2022) Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology 80: 322-337. https://doi.org/10.1111/his.14550.

Article  PubMed  Google Scholar 

Asa SL, Mete O (2018) Endocrine pathology: past, present and future. Pathol 50: 111–118. S0031–3025(17)30442–7. https://doi.org/10.1016/j.pathol.2017.09.003.

Uccella S, La Rosa S, Volante M, Papotti M (2018) Immunohistochemical biomarkers of gastrointestinal, pancreatic, pulmonary, and thymic neuroendocrine neoplasms. Endocr Pathol 29: 150-168. https://doi.org/10.1007/s12022-018-9522-y.

Article  PubMed  Google Scholar 

Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34: 228–252. S0091–3022(13)00039–3. https://doi.org/10.1016/j.yfrne.2013.07.005.

Komarnicki P, Musialkiewicz J, Stanska A, Maciejewski A, Gut P, Mastorakos G, Ruchala M (2022) Circulating neuroendocrine tumor biomarkers: past, present and future. J Clin Med 11. jcm11195542. jcm-11–05542. https://doi.org/10.3390/jcm11195542.

Willams JA (2023) Vasoctive Intestinal polypeptide or VIP. Pancreapedia. Exocrine Pancreas Knowledge Base. American Pancreatic Association. pancreapedia.org/molecules/vasoacative-intestinal-polypeptide-or-VIP; https://doi.org/10.3998/panc.2020.03

Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol 33: 6-26. https://doi.org/10.1007/s12022-022-09703-7.

Article  CAS  PubMed  Google Scholar 

Asa SL, Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, Nishioka H, Casar-Borota O, Uccella S, La Rosa S, Grossman AB, Ezzat S (2021) Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol 34: 1634-1650. https://doi.org/10.1038/s41379-021-00820-y.

Article  PubMed  Google Scholar 

Asa, S. L. and Perry, A. (2020) Tumors of the pituitary gland. Arlington VA: ARP Press.

Book  Google Scholar 

Asa SL, Ezzat S (2021) An update on pituitary neuroendocrine tumors leading to acromegaly and gigantism. J Clin Med. https://doi.org/10.3390/jcm10112254.

Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, Doherty GM, Herrera MF, Pasieka JL, Perrier ND, Silverberg SJ, Solorzano CC, Sturgeon C, Tublin ME, Udelsman R, Carty SE (2016) The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 151: 959–968. 2542667. https://doi.org/10.1001/jamasurg.2016.2310.

Akirov A, Asa SL, Larouche V, Mete O, Sawka AM, Jang R, Ezzat S (2019) The clinicopathological spectrum of parathyroid carcinoma. Front Endocrinol (Lausanne) 10: 731. https://doi.org/10.3389/fendo.2019.00731.

Article  PubMed  Google Scholar 

Thomas CM, Asa SL, Ezzat S, Sawka AM, Goldstein D (2019) Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines. Curr Oncol 26: 338-344. https://doi.org/10.3747/co.26.5539 conc-26-338.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhuge X, Wang Y, Chen X, Guo C (2020) Diabetes in patients with pancreatic neuroendocrine neoplasms. Front Endocrinol (Lausanne) 11: 615082. https://doi.org/10.3389/fendo.2020.615082.

Vinik A, Feliberti E, Perry RR (2000) Pancreatic Polypeptide (PPoma). In.

Maxwell JE, O'Dorisio TM, Bellizzi AM, Howe JR (2014) Elevated pancreatic polypeptide levels in pancreatic neuroendocrine tumors and diabetes mellitus: causation or association? Pancreas 43: 651–656. 00006676–201405000–00025. https://doi.org/10.1097/MPA.0000000000000082.

Young J, Haissaguerre M, Viera-Pinto O, Chabre O, Baudin E, Tabarin A (2020) Management of endocrine disease: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol 182: R29-R58. EJE-19–0877. https://doi.org/10.1530/EJE-19-0877.

Uccella S, Blank A, Maragliano R, Sessa F, Perren A, La Rosa S (2017) Calcitonin-producing neuroendocrine neoplasms of the pancreas: clinicopathological study of 25 cases and review of the literature. Endocr Pathol 28: 351-361. https://doi.org/10.1007/s12022-017-9505-4.

Article  CAS  PubMed  Google Scholar 

Alshaikh OM, Yoon JY, Chan BA, Krzyzanowska MK, Butany J, Asa SL, Ezzat S (2018) Pancreatic neuroendocrine tumor producing insulin and vasopressin. Endocr Pathol 29: 15-20. https://doi.org/10.1007/s12022-017-9492-5.

Article  CAS  PubMed  Google Scholar 

Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A (2022) Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol 33: 90-114. https://doi.org/10.1007/s12022-022-09704-6.

Article  CAS  PubMed  Google Scholar 

Dreijerink KMA, Rijken JA, Compaijen CJ, Timmers HJLM, van der Horst-Schrivers ANA, van Leeuwaarde RS, van Dam PS, Leemans CR, van Dam EWCM, Dickhoff C, Dommering CJ, de GP, Zwezerijnen GJC, van d, V, Menke-Van der Houven van Oordt CW, Hensen EF, Corssmit EPM, Eekhoff EMW (2019) Biochemically silent sympathetic paraganglioma, pheochromocytoma, or metastatic disease in SDHD mutation carriers. J Clin Endocrinol Metab 104: 5421–5426. 5514330. https://doi.org/10.1210/jc.2019-00202.

Osinga TE, Korpershoek E, de Krijger RR, Kerstens MN, Dullaart RP, Kema IP, van der Laan BF, van der Horst-Schrivers AN, Links TP (2015) Catecholamine-synthesizing enzymes are expressed in parasympathetic head and neck paraganglioma tissue. Neuroendocrinology 101: 289–295. 000377703. https://doi.org/10.1159/000377703.

Inzani F, Rindi G, Serra S (2016) The endocrine pancreas. In: Mete O, Asa SL, editors. Endocrine Pathology. Cambridge: Cambridge University Press. pp. 718-742.

Google Scholar 

Asa SL, La Rosa S, Basturk O, Adsay V, Minnetti M, Grossman AB (2021) Molecular pathology of well-differentiated gastro-entero-pancreatic neuroendocrine tumors. Endocr Pathol 32: 169-191. https://doi.org/10.1007/s12022-021-09662-5.

Article  PubMed  Google Scholar 

Uccella S, La Rosa S, Metovic J, Marchiori D, Scoazec JY, Volante M, Mete O, Papotti M (2021) Genomics of high-grade neuroendocrine neoplasms: well-differentiated neuroendocrine tumor with high-grade features (G3 NET) and neuroendocrine carcinomas (NEC) of various anatomic sites. Endocr Pathol 32: 192-210. https://doi.org/10.1007/s12022-020-09660-z.

Article  PubMed  Google Scholar 

Ikeda Y, Shen W-H, Ingraham HA, Parker KL (1994) Developmental expression of mouse steroidogenic factor-1, an essential regulator of the steroid hydroxylases. Mol Endocrinol 8: 654-662.

CAS  PubMed  Google Scholar 

Lala DS, Rice DA, Parker KL (1992) Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I. Mol Endocrinol 6: 1249-1258.

CAS  PubMed  Google Scholar 

Morohashi K-I, Honda S-I, Inomata Y, Handa H, Omura T (1992) A common trans-acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s. J Biol Chem 267: 17913-17919.

Article  CAS  PubMed  Google Scholar 

Mete O, Asa SL (2012) Morphological distinction of cortisol-producing and aldosterone-producing adrenal cortical adenomas: not only possible but a critical clinical responsibility. Histopathology.

Mete O, Asa SL, Giordano TJ, Papotti M, Sasano H, Volante M (2018) Immunohistochemical biomarkers of adrenal cortical neoplasms. Endocr Pathol 29: 137-149. https://doi.org/10.1007/s12022-018-9525-8.

Article  CAS  PubMed  Google Scholar 

Sun L, Jiang Y, Xie J, Zhu H, Wu L, Zhong X, Zhou W, Su T, Wang W (2021) Immunohistochemical analysis of CYP11B2, CYP11B1 and beta-catenin helps subtyping and relates with clinical characteristics of unilateral primary aldosteronism. Front Mol Biosci 8: 751770. 751770. https://doi.org/10.3389/fmolb.2021.751770.

Williams TA, Gomez-Sanchez CE, Rainey WE, Giordano TJ, Lam AK, Marker A, Mete O, Yamazaki Y, Zerbini MCN, Beuschlein F, Satoh F, Burrello J, Schneider H, Lenders JWM, Mulatero P, Castellano I, Knosel T, Papotti M, Saeger W, Sasano H, Reincke M (2021) International histopathology consensus for unilateral primary aldosteronism. J Clin Endocrinol Metab 106: 42–54. 5876946. dgaa484. https://doi.org/10.1210/clinem/dgaa484.

Murakami M, Rhayem Y, Kunzke T, Sun N, Feuchtinger A, Ludwig P, Strom TM, Gomez-Sanchez C, Knosel T, Kirchner T, Williams TA, Reincke M, Walch AK, Beuschlein F (2019) In situ metabolomics of aldosterone-producing adenomas. JCI Insight 4. 130356. https://doi.org/10.1172/jci.insight.130356.

De SK, Boulkroun S, Baron S, Nanba K, Wack M, Rainey WE, Rocha A, Giscos-Douriez I, Meatchi T, Amar L, Travers S, Fernandes-Rosa FL, Zennaro MC (2020) Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma. Hypertension 75: 1034-1044. https://doi.org/10.1161/HYPERTENSIONAHA.119.14177.

Article  CAS  Google Scholar 

Suzuki S, Minamidate T, Shiga A, Ruike Y, Ishiwata K, Naito K, Ishida A, Deguchi H, Fujimoto M, Koide H, Tatsuno I, Ikeda JI, Yamazaki Y, Sasano H, Yokote K (2020) Steroid metabolites for diagnosing and predicting clinicopathological features in cortisol-producing adrenocortical carcinoma. BMC Endocr Disord 20: 173. https://doi.org/10.1186/s12902-020-00652-y.

Article